Colorectal Cancer and Peripheral Neuropathy Study

Overview

About this study

The purpose of this study is to prospectively evaluate the development of neuropathy symptoms and corresponding changes in physical function in persons receiving oxaliplatin based chemotherapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria.

  • Patients must be adults, over the age of 18.
  • English speaking.
  • Scheduled to receive at least 3 months of oxaliplatin based chemotherapy, with no other highly neurotoxic agents (cisplatin, a taxane, a vinca-alkaloid, thalidomide, or bortezomib).  
  • Patients who are planning to receive oxaliplatin based chemotherapy as part of a clinical trial will not be specifically excluded from participating on this trial.
  • Participants who have medications prescribed for pain or anxiety will be included; however, they will be asked not to take any as needed (prn) pain or anxiety medications for 4 hours prior to QST, unless their pain or anxiety is severe (7 or higher on a scale of 0-10) in order to minimize influence of these medications on results.

Exclusion Criteria. 

  • Patients with pre-existing neuropathy (greater than 2 on a 0-10 scale), major psychiatric condition (bipolar or schizophrenia) or whose prior medical history could interfere with their ability to fulfill study requirements or provide accurate self-report data will be excluded from participation. 
  • Participants will be screened for these conditions by a review of their medical record and by collection of self-reported information.

Eligibility last updated 3/10/22. Questions regarding updates should be directed to the study team contact.

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Cindy Tofthagen, Ph.D.

Open for enrollment

Contact information:

Cindy Tofthagen Ph.D.

(904) 953-1409

Tofthagen.Cindy@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20521242

Mayo Clinic Footer